Roche plans to fast-track its anti-obesity drugs to challenge rivals Eli Lilly and Novo Nordisk in the booming market after unveiling promising data for a weight-loss pill.
Thomas Schinecker, chief executive of the Swiss pharmaceutical company, told the Financial Times that Roche’s first obesity drugs would come to market “significantly faster than people are expecting”, potentially by 2028.
The treatments, acquired in an up to $3.1bn takeover of biotech Carmot last year, includes a weight-loss jab set to enter phase II trials and a pill that has given users 6.1 per cent reduction in weight compared with a placebo after four weeks.
您已阅读17%（640字），剩余83%（3104字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。